Ovarian Cancer | Specialty

Utilizing Olaparib in Ovarian Cancer

July 2nd 2015

Biomarkers for Bevacizumab in Ovarian Cancer

July 2nd 2015

Frontline Therapy in Advanced Ovarian Cancer

July 2nd 2015

Bevacizumab in Platinum-Sensitive Ovarian Cancer

July 2nd 2015

Bevacizumab in Platinum-Resistant Ovarian Cancer

July 2nd 2015

Introduction: Molecular Testing in Ovarian Cancer

July 2nd 2015

Researchers Explore Immunotherapy With XBP1 Inhibition in Ovarian Cancer

June 17th 2015

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

Dr. Rafii Discusses Clinical Outcomes With Olaparib in Patients with Ovarian Cancer

June 16th 2015

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

Potential Bevacizumab Biomarker Identified in Ovarian Cancer

June 10th 2015

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

Rucaparib Response Rate Exceeds 80% in BRCA-mutant Ovarian Cancer

June 9th 2015

Treatment with the PARP inhibitor rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer

PD-1/PD-L1 Inhibitors Safe, Effective in Advanced Ovarian Cancer

June 3rd 2015

Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.

Dr. Coleman on Bevacizumab Across Tumor Types

May 13th 2015

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses how bevacizumab could be effective in tumor types beyond ovarian cancer.

Experts Offer Insight on BRCA1/2 Testing and Prophylactic Procedures

May 4th 2015

Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.

Dr. Xiu on HR Expression in Uterine Carcinosarcoma

May 4th 2015

Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

Biomarkers for Early Detection Essential to Major Progress in Ovarian Cancer

May 1st 2015

In an interview with OncLive, Robert C. Bast, Jr, MD, discussed his research using CA-125 levels and p53-autoantibodies as biomarkers for early detection of ovarian cancer.

Dr. Bast on Earlier Detection of Ovarian Cancer

April 22nd 2015

Robert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.

Olaparib Proves Versatile When Paired With AKT Inhibitor

April 22nd 2015

The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.

Olaparib Plus BKM120 Combo Gains Traction in Breast and Ovarian Cancers

April 21st 2015

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

Ovarian Cancer Expert Says Olaparib Label Is Too Restrictive

April 15th 2015

Clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib.

Dr. Markman on the Future of Treatment for Ovarian Cancer

April 13th 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.